Hem › Hjärntumörer › Kalifornien › Los Angeles
Kliniska studier för Hjärntumörer i Los Angeles, CA
16 studier för Hjärntumörer söker deltagare vid platser i och runt Los Angeles (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RekryterarFas 2
- Cedars-Sinai Medical Center, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekryterarFas 1/2
- University of Southern California, Los Angeles
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RekryterarFas 1/2
- Cedars-Sinai Medical Center, Los Angeles
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekryterarFas 1/2
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RekryterarFas 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekryterarFas 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RekryterarFas 1/2
- California Research Institute, Los Angeles
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
RekryterarFas 2
- Univ. of California Los Angeles, Los Angeles
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
RekryterarFas 2
- Children's Hospital Los Angeles, Los Angeles
REMASTer: REcurrent Brain Metastases After SRS Trial
Rekryterar
- UCLA, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekryterarFas 1/2
- University of California Los Angeles, Los Angeles
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
RekryterarFas 1
- Children's Hospital Los Angeles, Los Angeles
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RekryterarFas 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
Rekryterar
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekryterarFas 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RekryterarFas 2
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Hjärntumörer-studier i andra städer
- Houston, TX35 studier
- Boston, MA28 studier
- New York City, NY25 studier
- Washington, DC20 studier
- Miami, FL15 studier
- Durham, NC14 studier
- St. Louis, MO12 studier
- Rochester, MN11 studier
- Chicago, IL11 studier
- Cleveland, OH11 studier
- Baltimore, MD11 studier
- Columbus, OH11 studier
Andra studier i Los Angeles
- Icke-småcellig lungcancer87 studier
- Cancer (alla typer)74 studier
- Bröstcancer73 studier
- Prostatacancer61 studier
- Kolorektal cancer59 studier
- Metastaserande cancer57 studier
- Äggstockscancer50 studier
- Lungcancer45 studier
- Plattenepitelcancer i huvud och hals42 studier
- Bukspottkörtelcancer35 studier
- Endometriecancer34 studier
- Melanom34 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.